CoChat

Anti-obesity drug development

Bays, Harold, Dujovne, Carlos · 2002 · Expert Opinion on Investigational Drugs
Cited by 41

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

Abstract

Obesity accelerates morbidity and mortality and has been described by the World Health Organization (WHO) as an epidemic in many industrialised nations [101,102]. Diet, exercise and lifestyle recommendations have proven to be mostly ineffective in adequately preventing or treating the progression of this public health disease. Existing drug treatment is limited by the scarce number of safe and well-tolerated drugs with proven long-term efficacy in maintaining weight loss. Numerous anti-obesity drugs in development have promise. Yet, despite that obesity is the single most common nutritional problem in many developed nations and despite the devastating health consequences of this unchecked epidemic, investigational anti-obesity drugs face unique and significant challenges due to past and current experiences with anti-obesity drugs. It is anticipated that new anti-obesity drugs for this serious, multifaceted metabolic disease will become as safe and effective and as medically accepted as the treatment of other metabolic disorders such as hypertension, dyslipidaemia or Type 2 diabetes mellitus. This may be particularly important, given that these metabolic disorders may be largely due to or exacerbated by obesity itself.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1517/13543784.11.9.1189

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 13 references

Cited by

See all 41

Metadata

Authors
Bays, H., & Dujovne, C.
Venue
Expert Opinion on Investigational Drugs
Published
2002-09
Volume
11
Issue
9
Pages
1189-1204
ISSN
  • 1354-3784 (ISSN-L)
  • 1744-7658
OpenAlex
W2023709599
Cited by
41
References
13
FWCI
1.49
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Anti-obesity drug development. https://app.cochat.ai/papers/10.1517/13543784.11.9.1189
The paper
Bays, H., & Dujovne, C. (2002). Anti-obesity drug development. Expert Opinion on Investigational Drugs. https://doi.org/10.1517/13543784.11.9.1189

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.